Importantly, the combination of dual PI3K/AKT/mTOR inhibitors with IR significantly enhanced IR-induced regression of OSCC cells as efficiently as Cisplatin with IR treatment, indicating that dual PI3K/mTOR inhibition is a promising therapy that can potentially enhance the tumor response to radiation therapy in the clinic. Here, AKT1 is linked to neoplasm.